申请人:Cik Miroslav
公开号:US20080015225A1
公开(公告)日:2008-01-17
the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n is 0, 1 or 2;
R
2
represents hydroxy;
—X— represents C
2-4
alkynyl, C
1-12
alkyl optionally substituted with hydroxy or X represents a divalent radical of the formula
wherein; —X
1
— represents C
1-12
alkyl, phenyl or a divalent radical selected from the group consisting of
—X
2
— represents C
1-12
alkyl, C
1-4
alkyloxyC
1-4
alkyl, phenyl or a divalent radical of formula
—X
3
— represents phenyl or a divalent radical selected from the group consisting of
R
1
independently represents hydrogen, C
1-4
alkyl, C
1-4
alkyloxy-, Ar
1
, Ar
2
-carbonyl, Het
1
-C
1-4
alkyl, Het
2
, NR
3
R
4
—C
1-4
alkyl, Ar
3
-C
1-4
alkyloxy- or Het
4
-oxy-;
R
3
and R
4
each independently represents hydrogen, C
1-4
alkyl, C
1-4
alkyloxy-, or Het
3
;
Het
1
represents a heterocycle selected from pyridinyl, indolinyl, indolyl, benzimidazolyl, benzthiazolyl, benzisoxazolyl, thiazolyl, pyridinyl, or thiadiazolyl wherein said Het
1
is optionally substituted with one or where possible two or more substituents selected from the group consisting of hydroxy, halo, C
1-4
alkyloxycarbonyl-, C
1-4
alkyl-, C
1-4
alkyloxy- and C
1-4
alkyloxy-substituted with halo; in particular Het
1
represents a heterocycle selected from indolyl or pyridinyl;
Het
2
represents a heterocycle selected from indolyl, benzisoxazolyl or oxodiazolyl wherein said Het
2
is optionally substituted with one or where possible two or more substituents selected from the group consisting of hydroxy, halo, C
1-6
alkyl- and C
1-4
alkyloxy-;
Het
3
represents a heterocycle selected from benzimidazolyl, benzisoxazolyl or benzthiazolyl wherein said Het
3
is optionally substituted with one or where possible two or more substituents selected from the group consisting of hydroxy, halo, C
1-6
alkyl- and C
1-4
alkyloxy-; in particular Het
3
represents benzthiazolyl substituted with C
1-4
alkyloxy-;
Het
4
represents a heterocycle selected from benzimidazolyl, benzisoxazolyl or benzthiazolyl wherein said Het
4
is optionally substituted with one or where possible two or more substituents selected from the group consisting of hydroxy, halo, C
1-6
alkyl- and C
1-4
alkyloxy-; in particular Het
4
represents benzthiazolyl;
Ar
1
represents phenyl optionally substituted with halo, C
1-4
alkyl or C
1-4
alkyl substituted with one, two or three halo substituents;
Ar
2
represents phenyl optionally substituted with halo, C
1-4
alkyl or C
1-4
alkyl substituted with one, two or three halo substituents; in particular Ar
2
represents phenyl substituted with halo or trifluromethyl;
Ar
3
represents phenyl optionally substituted with halo, C
1-4
alkyl or C
1-4
alkyloxy-.